Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. GAVRETO (pralsetinib)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

GAVRETO (pralsetinib)

Medicine - Posted on Apr 21 2022
Active substance (DCI)
  • pralsetinib
history (2)
  • 3/23/22

    GAVRETO (pralsétinib) - Cancer bronchique

    Key points Favourable opinion for reimbursement, in second and later-line therapy only, as monotherapy for the treatment of ...
    CAV :
    54321
    icône flèche
  • 3/17/22

    GAVRETO (pralsétinib) - Cancer bronchique non à petites cellules

    Autorisation d’accès précoce refusée à la spécialité GAVRETO le 17 mars 2022 dans l'indication « en monothérapie dans le tra...
    icône flèche
Technical information
ATC code
  • L01EX23
Manufacturer
ROCHE
Presentation

GAVRETO 100 mg, gélule
Conditionnement 60 gélules - (Code CIP : 34009 302 414 4 8 ; Code UCD : 34008 900 148 8 5)

All our publications
    Anemia and hemoglobinopathies Congenital, genetic and rare diseases Drug therapy Metabolic diseases Paediatrics Respiratory tract cancers Urologic diseases - miscellaneous

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
uzDqRg8g2cPPJbdY